Bristol Myers Squibb in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the ...
The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.
Papillary muscle scarring (papSCAR) as detected by dark blood delayed-enhancement cardiovascular magnetic resonance (CMR) was ...
Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback